Opinion|Videos|July 31, 2024
Novel Agents/Combinations for aRCC
Author(s)Matthew T. Campbell, MD, MS, Rana R. McKay, MD
Matthew Campbell, MD, MS, and Rana McKay, MD, conclude by addressing the remaining unmet needs and persistent treatment challenges faced in managing patients with advanced renal cell carcinoma.
Advertisement
Episodes in this series
- What are some unmet needs and ongoing treatment challenges in patients with advanced RCC?
- Are there any novel agents or combinations you wish to mention?
- HIF2α inhibitor – (
Pal SK, et al. 2024 ASCO Annual Meeting. Abstract 4513 ). - HIF2α inhibitor – (
Bauer TM, et al. 2024 ASCO Annual Meeting. Abstract 273 ).
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
5